Aligos Therapeutics (ALGS) Share-based Compensation (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Share-based Compensation came in at $1.3 million in Q1 2026, up 2528.0% YoY from $50000.0 in Q1 2025, and up 142.62% on a QoQ basis from -$3.1 million in Q4 2025.
Aligos Therapeutics (ALGS) Share-based Compensation (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Share-based Compensation data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 2528.0% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 75.32% YoY) and the FY2025 annual result came in at $11.4 million, up 93.22% from the prior year.
- Share-based Compensation improved to $1.3 million in Q1 2026, from -$3.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.7 million in Q1 2023 to a low of -$10.0 million in Q4 2022.
- A 5-year average of -$185470.6 and a median of $199000.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 341.7% — and 2026, when it soared 2528.0%.
- Tracing ALGS's Share-based Compensation over 5 years: stood at -$10.0 million in 2022, then jumped by 125.87% to $2.6 million in 2023, then plunged by 341.7% to -$6.2 million in 2024, then soared by 50.62% to -$3.1 million in 2025, then jumped by 142.62% to $1.3 million in 2026.
- The last three Share-based Compensation figures came in at $1.3 million (Q1 2026), -$3.1 million (Q4 2025), and $199000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Aligos Therapeutics | 67.80 Mn | 37.36 Mn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Jun 30, 2026 | 1.36 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Sep 30, 2025 | 199,000.00 |
| Sep 30, 2025 | 199,000.00 |
| Jun 30, 2025 | 110,000.00 |
| Jun 30, 2025 | 110,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | -6.24 Mn |
| Dec 31, 2024 | -6.24 Mn |
| Sep 30, 2024 | 139,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Mar 31, 2024 | 148,000.00 |
| Mar 31, 2024 | 148,000.00 |